{"organizations": [], "uuid": "c7d35e6f8b57d251f8a1ce34c4997d826ac3915f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180121.html", "section_title": "Archive News &amp; Video for Sunday, 21 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/bioverativ-ma-sanofi-fr/sanofi-near-deal-to-buy-bioverativ-for-more-than-11-5-bln-wsj-idUSL2N1PH029", "country": "US", "domain_rank": 408, "title": "Sanofi near deal to buy Bioverativ for more than $11.5 bln -WSJ", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.611, "site_type": "news", "published": "2018-01-22T09:46:00.000+02:00", "replies_count": 0, "uuid": "c7d35e6f8b57d251f8a1ce34c4997d826ac3915f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/bioverativ-ma-sanofi-fr/sanofi-near-deal-to-buy-bioverativ-for-more-than-11-5-bln-wsj-idUSL2N1PH029", "ord_in_thread": 0, "title": "Sanofi near deal to buy Bioverativ for more than $11.5 bln -WSJ", "locations": [], "entities": {"persons": [{"name": "bioverativ", "sentiment": "negative"}, {"name": "paul simao", "sentiment": "none"}, {"name": "shubham kalia", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "bioverativ inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "sanofi sa", "sentiment": "negative"}, {"name": "wsj", "sentiment": "negative"}, {"name": "wall street journal", "sentiment": "none"}, {"name": "journal", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 21 (Reuters) - Sanofi SA is said to be near a deal to buy drug maker Bioverativ Inc for more than $11.5 billion, the Wall Street Journal reported, citing people familiar with the matter.\nThe deal, which could be announced as soon as Monday, would value Bioverativ at about $105 a share, the Journal reported. ( on.wsj.com/2mYJulp ) Sanofi and Bioverativ were not immediately available for comment outside regular business hours.\nReporting by Shubham Kalia in Bengaluru; Editing by Paul Simao\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://on.wsj.com/2mYJulp"], "published": "2018-01-22T09:46:00.000+02:00", "crawled": "2018-01-22T20:41:16.003+02:00", "highlightTitle": ""}